[논문]Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review

Park, Joon Oh; Oh, Do-Youn; Hsu, Chiun; Chen, Jen-Shi; Chen, Li-Tzong; Orlando, Mauro; Kim, Jong Seok; Lim, Ho Yeong

doi:10.4143/crt.2014.308

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review 원문보기

Cancer research and treatment : official journal of Korean Cancer Association, v.47 no.3, 2015년, pp.343 - 361

Park, Joon Oh (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea) , Oh, Do-Youn (Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea) , Hsu, Chiun (Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan) , Chen, Jen-Shi (Department of Internal Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan) , Chen, Li-Tzong (National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan) , Orlando, Mauro (Eli Lilly Interamerica Inc., Buenos Aires, Argentina) , Kim, Jong Seok (Eli Lilly Korea Ltd., Seoul, Korea) , Lim, Ho Yeong (Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea)

Abstract ▼ AI-Helper

Evidence suggests that combined gemcitabine-cisplatin chemotherapy extends survival in patients with advanced biliary tract cancer (BTC). We conducted a systematic review in order to collate this evidence and assess whether gemcitabine-cisplatin efficacy is influenced by primary tumor site, disease stage, or geographic region, and whether associated toxicities are related to regimen. MEDLINE (1946-search date), EMBASE (1966-search date), ClinicalTrials. gov (2008-search date), and abstracts from major oncology conferences (2009- search date) were searched (5 Dec 2013) using terms for BTC, gemcitabine, and cisplatin. All study types reporting efficacy (survival, response rates) or safety (toxicities) outcomes of gemcitabine-cisplatin in BTC were eligible for inclusion; efficacy data were extracted from prospective studies only. Evidence retrieved from one meta-analysis (abstract), four randomized controlled trials, 12 nonrandomized prospective studies, and three retrospective studies supported the efficacy and safety of gemcitabine-cisplatin for BTC. Median overall survival ranged from 4.6 to 11.7 months, and response rate ranged from 17.1% to 36.6%. Toxicities were generally acceptable and manageable. Heterogeneity in study designs and data collected prevented formal meta-analysis, however exploratory assessments suggested that efficacy did not vary with primary tumor site (gallbladder vs. others), disease stage (metastatic vs. locally advanced), or geographic origin (Asia vs. other). Incidence of grade 3/4 toxicities was not related to gemcitabine dose or cisplatin frequency. Despite individual variation in study designs, the evidence presented suggests that gemcitabine-cisplatin is effective in patients from a diverse range of countries and with heterogeneous disease characteristics. No substantial differences in toxicity were observed among the different dosing schedules of gemcitabine and cisplatin.

주제어

참고문헌 (44)

1 Noel MS Hezel AF New and emerging treatment options for biliary tract cancer Onco Targets Ther 2013 6 1545 52 24204165

상세보기
2 Sasaki T Isayama H Nakai Y Koike K Current status of chemotherapy for the treatment of advanced biliary tract cancer Korean J Intern Med 2013 28 515 24 24009445

상세보기
3 Randi G Malvezzi M Levi F Ferlay J Negri E Franceschi S Epidemiology of biliary tract cancers: an update Ann Oncol 2009 20 146 59 18667395

상세보기
4 Hundal R Shaffer EA Gallbladder cancer: epidemiology and outcome Clin Epidemiol 2014 6 99 109 24634588
5 Leonard GD O'Reilly EM Biliary tract cancers: current concepts and controversies Expert Opin Pharmacother 2005 6 211 23 15757418

상세보기
6 Hezel AF Zhu AX Systemic therapy for biliary tract cancers Oncologist 2008 13 415 23 18448556

상세보기
7 Glimelius B Hoffman K Sjoden PO Jacobsson G Sellstrom H Enander LK Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 1996 7 593 600 8879373

상세보기
8 Seufferlein T Bachet JB Van Cutsem E Rougier P ESMO Guidelines Working Group Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2012 23 Suppl 7 vii33 40 22997452
9 Gemzar (gemcitabine for injection) [prescribing information] Indianapolis Eli Lilly and Company 2013
10 Sun C Ansari D Andersson R Wu DQ Does gemcitabinebased combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012 18 4944 58 23002368
11 Gruenberger B Schueller J Heubrandtner U Wrba F Tamandl D Kaczirek K Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study Lancet Oncol 2010 11 1142 8 21071270

상세보기
12 Lee J Park SH Chang HM Kim JS Choi HJ Lee MA Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study Lancet Oncol 2012 13 181 8 22192731

상세보기
13 Sharma A Dwary AD Mohanti BK Deo SV Pal S Sreenivas V Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study J Clin Oncol 2010 28 4581 6 20855823

상세보기
14 Zhu AX Meyerhardt JA Blaszkowsky LS Kambadakone AR Muzikansky A Zheng H Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study Lancet Oncol 2010 11 48 54 19932054

상세보기
15 Eckel F Schmid RM Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials Br J Cancer 2007 96 896 902 17325704

상세보기
16 Valle JW Wasan H Johnson P Jones E Dixon L Swindell R Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study. The UK ABC-01 Study Br J Cancer 2009 101 621 7 19672264
17 Valle J Wasan H Palmer DH Cunningham D Anthoney A Maraveyas A Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 2010 362 1273 20375404

상세보기
18 Yonemoto N Furuse J Okusaka T Yamao K Funakoshi A Ohkawa S A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer Jpn J Clin Oncol 2007 37 843 51 17942578

상세보기
19 Park I Lee JL Ryu MH Kim TW Lee SS Park DH Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy Cancer 2009 115 4148 55 19536892
20 Mahfouf H Chemotherapy using gemcitabine (G) plus cisplatin (C) in locally in stage III and IV gallbladder and biliary tract J Clin Oncol 2010 28 Suppl
21 Singh D Kumar S Sonkar AA Jaiswal S Mishra A Role of low dose prolonged infusion of gemcitabine and cisplatin in inoperable carcinoma gallbladder: a prospective pilot study Ann Oncol 2011 22 v83
22 Charoentum C Thongprasert S Chewaskulyong B Munprakan S Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma World J Gastroenterol 2007 13 2852 4 17569122
23 Doval DC Sekhon JS Gupta SK Fuloria J Shukla VK Gupta S A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer Br J Cancer 2004 90 1516 20 15083178

상세보기
24 Eckmann KR Patel DK Landgraf A Slade JH Lin E Kaur H Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis Gastrointest Cancer Res 2011 4 155 60 22295126

상세보기
25 Giuliani F Gebbia V Maiello E Borsellino N Bajardi E Colucci G Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM) Ann Oncol 2006 17 Suppl 7 vii73 7 16760299
26 Goldstein D Gainford MC Brown C Tebbutt N Ackland SP van Hazel G Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas Cancer Chemother Pharmacol 2011 67 519 25 20461378

상세보기
27 Kang MJ Lee JL Kim TW Lee SS Ahn S Park DH Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma Acta Oncol 2012 51 860 6 22559158

상세보기
28 Kim ST Park JO Lee J Lee KT Lee JK Choi SH A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer Cancer 2006 106 1339 46 16475213
29 Lee GW Kang JH Kim HG Lee JS Lee JS Jang JS Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma Am J Clin Oncol 2006 29 127 31 16601429

상세보기
30 Lee J Kim TY Lee MA Ahn MJ Kim HK Lim HY Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas Cancer Chemother Pharmacol 2008 61 47 52 17364190

상세보기
31 Meyerhardt JA Zhu AX Stuart K Ryan DP Blaszkowsky L Lehman N Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer Dig Dis Sci 2008 53 564 70 17597402

상세보기
32 Okusaka T Nakachi K Fukutomi A Mizuno N Ohkawa S Funakoshi A Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan Br J Cancer 2010 103 469 74 20628385

상세보기
33 Park BK Kim YJ Park JY Bang S Park SW Chung JB Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer J Gastroenterol Hepatol 2006 21 999 1003 16724985

상세보기
34 Thongprasert S Napapan S Charoentum C Moonprakan S Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma Ann Oncol 2005 16 279 81 15668284

상세보기
35 Wu CE Hsu HC Shen WC Lin YC Wang HM Chang JW Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis Chang Gung Med J 2012 35 420 7 23127347

상세보기
36 Charoentum C Chotirosniramit A Chitapanarux T Sirivanichai C Lertprasertsuke N Chewaskulyong B Attenuated dose of gemcitabine with cisplatin in patients (pts) with unresectable or metastatic biliary tract cancer (ABC): results of single Thai institution J Clin Oncol 2013 31 Suppl 4 265
37 Mizuno N Valle JW Furuse J Jitlal M Beare S Wasan H Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomized trials J Clin Oncol 2013 31 Suppl 4120
38 Valle JW Furuse J Jitlal M Beare S Mizuno N Wasan H Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials Ann Oncol 2014 25 391 8 24351397

상세보기
39 Thatikonda C Miller A Iyer R Meta analysis of oxaliplatinbased combination chemotherapy for advanced gallbladder and bile duct cancers (AGBC) Am J Gastroenterol 2010 105 S72
40 Julka PK Puri T Rath GK A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma Hepatobiliary Pancreat Dis Int 2006 5 110 4 16481295
41 Williams KJ Picus J Trinkhaus K Fournier CC Suresh R James JS Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study HPB (Oxford) 2010 12 418 26 20662793

상세보기
42 Gallardo J Rubio B Villanueva L Barajas O Gallbladder cancer, a different disease that needs individual trials J Clin Oncol 2005 23 7753 4 16234545

상세보기
43 Bridgewater J Galle PR Khan SA Llovet JM Park JW Patel T Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma J Hepatol 2014 60 1268 89 24681130

상세보기
44 Heinemann V Quietzsch D Gieseler F Gonnermann M Schonekas H Rost A Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 2006 24 3946 52 16921047

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (44)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트